Authored By: Sarah
04 Jul 2024

 RNAi Drug Delivery Market Size to grow by USD 109.73 billion between 2023-2027

According to a research report “ RNAi Drug Delivery Market” by Technology (Nanoparticle drug delivery, Pulmonary drug delivery, Nucleic acid drug delivery, Aptamer drug delivery ) Application (Infectious diseases, Oncology, Cardiology, Neurology, Others ) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 109.73 billion, at a CAGR of growth_momentum_prefix 20.83% during the forecast period. In the realm of RNAi drug delivery, the high specificity of RNAi therapeutics is a key advantage. The mechanism of gene inhibition is underpinned by the base pair complementarity between the RNA and target gene. Hydrogen bonds form when adenine (A) pairs with uracil (U), and cytosine (C) pairs with guanine (G), ensuring a strong bond between the RNA and target sequence. This base pairing is crucial, as it enables RNAi and antisense nucleotides to selectively bind to their designated genes or targets, making RNAi therapy a promising modality in gene silencing applications.

Browse market data tables, figures, and in-depth TOC on “RNAi Drug Delivery Market” by Technology (Nanoparticle drug delivery, Pulmonary drug delivery, Nucleic acid drug delivery, Aptamer drug delivery ) Application (Infectious diseases, Oncology, Cardiology, Neurology, Others ) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample

 

By Technology, the Nanoparticle drug delivery segment is projected to dominate the market size in 2024

In the realm of pharmaceuticals, RNAi (Ribonucleic Acid interference) therapies represent a cutting-edge innovation for combating various infectious diseases, such as hepatitis, influenza virus, and HIV-AIDS. The primary advantage of these therapies lies in their ability to evade the immune response in patients. Extensive research initiatives are underway to utilize oligonucleotides for silencing genes within infectious agents like respiratory syncytial virus and hepatitis C and B viruses. The global incidence of severe infectious diseases, including hepatitis, is on the rise, necessitating the development of novel therapeutic solutions. siRNAs (small interfering RNAs) can be naturally sourced or synthetically produced to specifically target mRNA in mammalian cells, making them an essential tool in the pharmaceutical industry's arsenal against infectious diseases.

By Application, Infectious diseases  segment is expected to hold the largest market size for the year 2024

In the healthcare industry, nanotechnology's application in drug delivery systems is gaining significant traction. Nanoparticles, with their unique properties at the nanoscale, serve as effective diagnostic tools and vehicles for delivering therapeutic agents to precise targets. This targeted delivery system offers numerous advantages in the treatment of chronic human diseases, enabling the administration of precise medications to specific locations. Notably, RNAi therapeutics have shown promising results in various diseases, and the use of nanoparticles enhances their efficiency by ensuring controlled and effective delivery. Key characteristics of nanoparticles, including size and surface properties, play a crucial role in the successful delivery of RNAi drugs. Recent advancements in nanoparticle drug delivery systems have demonstrated notable applications in the treatment of cancer, genetic disorders, and infectious diseases.

North America is forecasted to hold the largest market size by region in 2024

In North America, the rising incidence of cancer, metabolic, and rare diseases can be attributed to unhealthy lifestyle choices, such as excessive smoking and alcohol consumption. The advancement of diagnostic technologies has enabled the identification of previously undetected rare diseases, leading market players and researchers to focus on developing RNAi therapies. For instance, Alnylam's collaboration with Novo Nordisk's Dicerna subsidiary in April 2020 to advance investigational RNAi therapeutics for alpha-1 liver disease underscores this trend. These factors are expected to fuel the growth of the RNAi drug delivery market in North America throughout the forecast period.

The RNAi Drug Delivery Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Alnylam Pharmaceuticals Inc.
  • Arbutus Biopharma Corp.
  • Arrowhead Pharmaceuticals Inc.
  • Bayer AG
  • Benitec Biopharma Inc.
  • BioNTech SE
  • Bristol Myers Squibb Co.
  • CureVac AG
  • e therapeutics plc
  • F. Hoffmann La Roche Ltd.
  • Novartis AG
  • Novo Nordisk AS
  • Phio Pharmaceuticals
  • Sanofi
  • Silence Therapeutics plc
  • Silenseed Inc.
  • siRNAgen Therapeutics Corp.
  • Sirnaomics Inc.
  • Sylentis S.A.
  • Thermo Fisher Scientific Inc.
  • TransCode Therapeutics Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The RNAi drug delivery market is a rapidly growing sector in the biotechnology industry, driven by the advancements in RNA interference technology and its potential applications in various therapeutic areas. RNAi therapeutics utilize small interfering RNA (siRNA), RNA aptamers, and short hairpin RNA (shRNA) to target and degrade specific RNA molecules, thereby inhibiting gene expression. Key therapeutic areas for RNAi therapeutics include chronic medical disorders such as ophthalmological disorders, where Pegaptanib sodium (Macugen) is approved for the treatment of neovascular age-related macular degeneration. Other therapeutic areas include oncological disorders, urological disorders, neurological disorders, cardiovascular disorders, chronic metabolic disorders, infectious diseases, and pulmonary disorders. RNAi therapeutics can be delivered through various methods, including topical, intraperitoneal, intra-dermal, and intravenous administration. The use of nanoparticles and aptamers as delivery vehicles has improved the efficacy and specificity of RNAi therapeutics. However, challenges such as RNA degradation and off-target effects remain. Nucleic acid-based therapeutics, including RNAi therapeutics, target mutations and gene expression in diseases. siRNA and shRNA can be designed to target specific mRNA sequences, while miRNA can be used to modulate gene expression. Overall, the RNAi drug delivery market holds immense potential in the development of novel therapeutics for various diseases.

Market Research Overview

The RNAi drug delivery market is a rapidly growing sector in the healthcare industry, with a significant focus on hospitals and clinics as key end customers. This market encompasses various pipeline products, including mRNA therapeutics for rare genetic diseases and vaccines, such as those in HIV vaccine trials. RNA synthesis is a crucial aspect of RNAi therapeutics, which utilize small interfering RNA (siRNA), microRNAs (miRNA), shRNA, and RNA aptamers for gene silencing. Investors and funders are increasingly interested in RNAi therapeutics due to their potential in treating various diseases, including cancer, cardiovascular diseases (CVDs), neurological disorders, chronic metabolic disorders, and infectious diseases. Technological advancements, such as nanotechnology and synthetic delivery carriers, are essential in overcoming challenges like RNA degradation by RNases and immunogenicity. Key therapeutic areas for RNAi therapeutics include ophthalmological disorders, oncological disorders, urological disorders, and infectious diseases. Notable products in the market include Pegaptanib sodium (Macugen) for age-related macular degeneration and RNA aptamers for targeting viral antigens in antiviral drugs. The geriatric population and chronic medical disorders are significant markets for RNAi therapeutics, with applications in pulmonary, topical delivery, intraperitoneal, intra dermal, and intravenous administration. The development of RNAi therapeutics for gene expression modulation and altered cellular molecules, such as metabolites and DNA, is a promising area for personalized medicines. In summary, the RNAi drug delivery market is a dynamic and evolving sector with a vast potential to impact various healthcare areas, from treating rare genetic diseases to developing vaccines and antiviral drugs. Technological advancements, including nanotechnology and synthetic delivery carriers, are essential in overcoming challenges and expanding the applications of RNAi therapeutics.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio